BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.575
-0.013 (-2.19%)
Nov 21, 2024, 2:18 PM EST - Market open
BioXcel Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 2.28 | 1.38 | 0.38 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 83.25% | 268.00% | - | - | - | - | Upgrade
|
| Cost of Revenue | 2.03 | 1.26 | 0.02 | - | - | - | Upgrade
|
| Gross Profit | 0.25 | 0.12 | 0.36 | - | - | - | Upgrade
|
| Selling, General & Admin | 40 | 83.41 | 68.76 | 54.59 | 24.65 | 7.96 | Upgrade
|
| Research & Development | 34.47 | 84.33 | 91.24 | 52.34 | 57.65 | 25.64 | Upgrade
|
| Operating Expenses | 74.47 | 167.74 | 160 | 106.94 | 82.3 | 33.6 | Upgrade
|
| Operating Income | -74.22 | -167.62 | -159.65 | -106.94 | -82.3 | -33.6 | Upgrade
|
| Interest Expense | -14.53 | -13.31 | -8.21 | -0.04 | -0.03 | -0.02 | Upgrade
|
| Interest & Investment Income | 3.18 | 5.65 | 2.53 | 0.04 | 0.16 | 0.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 16.98 | 0.39 | -0.43 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -68.59 | -174.89 | -165.76 | -106.93 | -82.17 | -32.97 | Upgrade
|
| Merger & Restructuring Charges | -2.41 | -4.16 | - | - | - | - | Upgrade
|
| Pretax Income | -71 | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 | Upgrade
|
| Net Income | -71 | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 | Upgrade
|
| Net Income to Common | -71 | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 | Upgrade
|
| Shares Outstanding (Basic) | 36 | 29 | 28 | 26 | 22 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 36 | 29 | 28 | 26 | 22 | 16 | Upgrade
|
| Shares Change (YoY) | 24.19% | 3.98% | 6.23% | 21.63% | 33.11% | 11.79% | Upgrade
|
| EPS (Basic) | -1.99 | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 | Upgrade
|
| EPS (Diluted) | -1.99 | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 | Upgrade
|
| Free Cash Flow | - | -155.03 | -135.48 | -82.6 | -66.67 | -27.97 | Upgrade
|
| Free Cash Flow Per Share | - | -5.32 | -4.84 | -3.13 | -3.07 | -1.72 | Upgrade
|
| Gross Margin | 11.03% | 8.70% | 94.67% | - | - | - | Upgrade
|
| Operating Margin | -3260.90% | -12146.30% | -42572.00% | - | - | - | Upgrade
|
| Profit Margin | -3119.33% | -12974.86% | -44201.87% | - | - | - | Upgrade
|
| Free Cash Flow Margin | - | -11233.77% | -36128.00% | - | - | - | Upgrade
|
| EBITDA | -73.91 | -167.3 | -159.32 | -106.64 | -82.11 | -33.45 | Upgrade
|
| D&A For EBITDA | 0.31 | 0.32 | 0.33 | 0.3 | 0.19 | 0.16 | Upgrade
|
| EBIT | -74.22 | -167.62 | -159.65 | -106.94 | -82.3 | -33.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.